EISAI
Eisai is a human health care company that provides products and services to its patients and their families under any healthcare system. Eisai specializes in the integrated pharmaceutical business that operates in business groups it focuses on oncology and neurology, dementia-related diseases and neurodegenerative diseases. The company was founded in 1941 and headquartered in Tokyo, Japan.
EISAI
Industry:
Biotechnology Health Care Health Insurance Pharmaceutical
Founded:
1941-12-06
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.eisai.co.jp
Total Employee:
10001+
Status:
Active
Contact:
81-3-3817-3700
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Apache Global Site Tag
Similar Organizations
Advantage Risk Management
Advantage Risk Management is a mental health care company that provides comprehensive mental health services for companies.
Eisai Europe
Eisai Europe is a human health care company that provides products and services to its patients.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Jaber Ibn Hayyan Pharmaceutical
Jaber Ibn Hayyan Pharmaceutical manufactures drugs like anti-biotic, non-antibiotic , topical, oral and others.
UNI PHARMA
Unipharma is to provide healthcare products and outstanding services for both pharmaceutical and animal healthcare products.
Current Employees Featured
Yuji Matsue Chairman & CEO @ Eisai
Chairman & CEO
Wil Foster Director Regulatory Affairs @ Eisai
Director Regulatory Affairs
Haruo Naito CEO @ Eisai
CEO
Yasushi Okada COO @ Eisai
COO
Chad Swanson Executive Director, Neurology Business Group; Clinical Research @ Eisai
Executive Director, Neurology Business Group; Clinical Research
2019-07-01
Eran Nadav Business Development Director @ Eisai
Business Development Director
Stewart Geary Deputy Director @ Eisai
Deputy Director
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-01-07 | AkaRx | AkaRx acquired by Eisai | 255 M USD |
| 2007-03-22 | Morphotek | Morphotek acquired by Eisai | 325 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-09 | LIFENET INSURANCE COMPANY | Eisai investment in Post-IPO Equity - LIFENET INSURANCE COMPANY | 300 M JPY |
| 2022-01-27 | Ractigen Therapeutics | Eisai investment in Series A - Ractigen Therapeutics | 30 M USD |
| 2021-09-09 | Neuroglee Therapeutics | Eisai investment in Series A - Neuroglee Therapeutics | 10 M USD |
| 2021-05-04 | ŌURA | Eisai investment in Series C - ŌURA | 100 M USD |
| 2021-04-05 | Allm | Eisai investment in Series A - Allm | 5.6 B JPY |
| 2020-12-03 | Neuroglee Therapeutics | Eisai investment in Pre Seed Round - Neuroglee Therapeutics | 2.3 M USD |
| 2020-11-05 | Unlearn.AI | Eisai investment in Series A - Unlearn.AI | 3 M USD |
| 2020-04-10 | Darmiyan | Eisai investment in Seed Round - Darmiyan | 6.43 M USD |
| 2019-12-12 | Numab | Eisai investment in Series B - Numab | 22 M CHF |
| 2019-05-09 | Allm | Eisai investment in Corporate Round - Allm | N/A |
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-27 | Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership |
Official Site Inspections
http://www.eisai.co.jp Semrush global rank: 333.99 K Semrush visits lastest month: 181.62 K
Unable to get host informations!!!
More informations about "Eisai"
Eisai (company) - Wikipedia
Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. The American subsidiary of the company, Eisai Inc., was established in 1995. On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and c…See details»
Corporate Executives | Corporate Information | Eisai …
Jun 14, 2024 Chairman & CEO, Eisai Europe Ltd. Tatsuyuki Yasuno. Senior Vice President President, Americas Region Chairman & CEO, Eisai Inc. Yanhui Feng. Senior Vice President President, Eisai China Holdings Ltd. Masatomi …See details»
Eisai Co., Ltd.｜A human health care company
5 days ago EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024. June 21, 2024. Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners” June 3, …See details»
Org Chart Eisai - The Official Board
Organizational Chart of Eisai. Eisai www.eisai.co.jp. has 101 executives and 12 subsidiaries +81 338 173 700; Add an executive. Eisai (4523) News . Anything missing? We search for you. …See details»
Corporate values and responsibilities | Eisai US
INTEGRITY AT EISAI: ROOTED IN ALL WE DO. Integrity is a core value to the Eisai organization. What we mean by integrity is that we strive as a Company to be honest and open in our actions and mindful of our responsibilities to …See details»
Eisai Europe
Eisai in numbers With operations in Asia, Australia, Europe, The Middle East, Latin America, New Zealand and the United States, we employ more than 10,000 people worldwide. 0See details»
A research-based pharmaceutical company | Eisai US
6 days ago Eisai is a research-based human health care company that discovers, develops and markets phamaceutical products internationally. Learn more about Eisai today.See details»
Eisai at a Glance | About Eisai - Eisai Co., Ltd.
Eisai is promoting initiatives for improving access to medicines in developing and emerging countries. Eisai is committed to supplying tablets free of charge from its Vizag Plant in India to millions of people at risk in lymphatic filariasis endemic …See details»
Our human health care mission | Eisai Inc. - Eisai Co., Ltd.
To perpetuate a spirit of bold, innovative problem-solving throughout our organization, Eisai follows the SECI Process *: SOCIALIZATION: Each year, every Eisai employee spends at least 1% of their working time — a total of two …See details»
Meet the inspiring leadership team | Eisai US
In 2020, Mr. Yasuno returned to the U.S. as President of Eisai Inc. and the Americas Region, successfully navigating the business and leading the organization through the critical pandemic period. He relocated the company …See details»
Eisai - The Org
Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical …See details»
Eisai Australia
Our work at Eisai prioritises patients and their families through our focus to continually improve the benefits that health care can provide. We call this human health care (hhc) Eisai in …See details»
Eisai - Crunchbase Company Profile & Funding
Eisai is a human healthcare company that provides products and services to its patients and their families under any healthcare system. They specialize in an integrated pharmaceutical …See details»
Eisai Innovation, Inc.
President of Eisai Innovation, Inc. Yoshiharu Mizui founded Eisai Innovation, Inc. in 2019. Prior to that he was a global head of the BD/Strategy Department in Oncology Business Group at Eisai …See details»
Compensation & Benefits at Eisai
Eisai offers attractive salaries, performance incentives, top-tier benefits, a wellness program, and innovative work-life solutions. EISAI offers an amazingly supportive, diverse culture where you …See details»
REFORM OF GLOBAL RESEARCH AND DEVELOPMENT …
Jul 15, 2022 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company has reformed its global Research and Development (R&D) organization from …See details»
Eisai Medical Oncology & Neurology Resources for HCPs
At Eisai, everything we do is guided by a simple principle: patients and their families come first, and we have a responsibility to listen to and learn from them. Oncology Neurology Clinical …See details»
ORGANIZATIONAL REFORM AND CHANGES OF CORPORATE …
Aug 1, 2023 To maximize the value of launched products and accelerate the development of new drugs that will lead future growth of Eisai, and promote the efficiency of clinical research …See details»